Physician profile
Chandre C Gowda
NPI 1235162322
$4,174.04
in general payments reported to CMS, 2019-2025
29 companies · $23.44 in 2025
The $23.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $366 · 2021: $1,081 · 2022: $1,235 · 2023: $879 · 2024: $225 · 2025: $23.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,189.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $547.33 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $438.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $375.28 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $201.96 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $172.82 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $144.43 | 2019-2021 | |
| Allergan, INC. | $134.58 | 2020 | |
| Merck Sharp & Dohme LLC | $112.23 | 2021-2023 | Verquvo, Steglujan, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $112.07 | 2019-2024 | Eliquis |
| Dexcom, INC. | $111.40 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $110.29 | 2021-2024 | Veozah |
| Abbott Laboratories | $74.41 | 2021-2023 | Freestyle Libre 3 |
| Lundbeck LLC | $52.46 | 2020-2023 | Rexulti |
| Lucid Diagnostics INC. | $49.49 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $48.49 | 2021 | |
| Pfizer INC. | $40.55 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.57 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $31.55 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.48 | 2022 | |
| Almatica Pharma LLC | $30.13 | 2022 | |
| Lilly USA, LLC | $26.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.11 | 2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.49 | 2023 | |
| Nevro Corp. | $16.35 | 2022 | |
| Hologic Sales and Service, LLC | $14.56 | 2020 | |
| Neurocrine Biosciences, INC. | $13.43 | 2021 | |
| Bardy Diagnostics, INC. | $12.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandre Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.